Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Main Inclusion Criteria:

• Clinical diagnosis of COPD (Chronic Obstructive Pulmonary Disease)

• Currently stable COPD with no change in COPD treatment in the prior 4 weeks

Main Exclusion Criteria:

• Clinical diagnosis of asthma

• Poorly controlled COPD

• Regular need for daily oxygen therapy